Gates Package — page 246

Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership Director, Division of Clinical Innovation National Center for Advancing Translational Sciences, NIH Clifford Lane, M.D. Deputy Director, Clinical Research and Special Projects; Director, Division of Clinical Research National Institute of Allergy and Infectious Diseases, NIH John Lepore, M.D. Senior Vice President, R&D Pipeline GlaxoSmithKline Douglas Lowy, M.D. Principal Deputy Director National Cancer Institute, NIH Peter Marks, M.D., Ph.D. Director, Center for Biologics Evaluation and Research U.S. Food and Drug Administration Hilary Marston, M.D., M.P.H. Medical Officer and Policy Advisor for Pandemic Preparedness National Institute of Allergy and Infectious Diseases, NIH John Mascola, M.D. Director, Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases, NIH David Meeker, M.D. Chairman, President and Chief Executive Officer Rhythm Therapeutics Nancy Messonnier, M.D. Director, Center for the National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention Mene Pangalos, Ph.D. Executive Vice President, BioPharmaceuticals R&D AstraZeneca William Pao, M.D., Ph.D. Head of Pharma Research and Early Development (pRED) Roche Roger Perlmutter, M.D., Ph.D. Executive Vice President and President, Merck Research Laboratories Merck Robert Plenge, M.D., Ph.D.